# AI drug discovery startup funding

> Developing situation record from CLSTR: https://clstr.news/situations/ai-drug-discovery-startup-funding
> Updated: 2026-11-19T09:54:01.000Z. Sources: 2. Developments: 2.

The biotechnology and medical AI sectors have seen significant investment in platforms designed to accelerate drug discovery through artificial intelligence.

In late October 2026, the biotechnology spin-off ALLOX secured $10.5 million in seed funding to expand its platform, which integrates high-throughput genetics and AI to target difficult biological areas like protein-protein interactions. Following this, in November 2026, Boltz PBC raised $110 million in Series A funding to advance its biomolecular modeling and protein design technology, specifically aiming to streamline small molecule research by using AI models to identify promising candidates.

## Timeline

### 2026-11-19: Boltz raises $110 million for medical AI drug discovery

Medical AI startup Boltz has raised $110 million in Series A funding, led by Bessemer Venture Partners, to advance its BoltzMol-1 model for accelerating small molecule drug discovery.

2 sources. https://clstr.news/cluster/boltz-raises-110-million-for-medical-ai-drug-discovery

### 2026-10-29: ALLOX secures $10.5 million in seed funding for drug discovery platform

Biotech company ALLOX has raised $10.5 million in seed funding to scale its AI and genetics-driven platform for discovering new small-molecule drug targets.

4 sources. https://clstr.news/cluster/allox-secures-105-million-in-seed-funding-for-drug-discovery-platform

---
Cite as: AI drug discovery startup funding. CLSTR, https://clstr.news/situations/ai-drug-discovery-startup-funding
